Streetbeat News

Analyst Ratings

STZ

Roth MKM analyst Bill Kirk maintains a 'Buy' rating on Constellation Brands (NYSE:STZ) and raises the price target from $270 to $284.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 1:13 pm

STRL

DA Davidson analyst Brent Thielman maintains a 'Buy' rating on Sterling Infrastructure (NASDAQ:STRL) and raises the price target from $52 to $65.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 1:12 pm

SST

System1 (NYSE:SST) reported Q1 sales of $167.85 million, missing the analyst consensus estimate of $214.50 million by 21.75 percent.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 1:04 pm

GNFT

HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Genfit (NASDAQ:GNFT) and raises the price target from $9 to $11.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 1:03 pm

THTX

Canaccord Genuity analyst Edward Nash assumes Theratechnologies (NASDAQ:THTX) with a Hold rating and announces a price target of $2.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 1:02 pm

BIIB

IONS

NVS

Biogen Inc has announced new data on its drug Spinraza, showing improved motor function in infants and toddlers with spinal muscular atrophy (SMA) who had previously been treated with Novartis AG's gene therapy, Zolgensma. The data comes from an ongoing two-year, phase 4 open-label study. Analysts from William Blair suggest that the results indicate the added benefit of Spinraza treatment and predict that it will remain a significant contributor to Biogen's revenues, as well as those of its development partner, Ionis Pharmaceuticals Inc.

Portfolio Pulse from Vandana Singh

July 03, 2023 | 12:36 pm

VRTX

Morgan Stanley analyst Matthew Harrison has reiterated an Equal-Weight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $305 to $340.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:34 pm

SPLK

Morgan Stanley analyst Keith Weiss has reiterated an Equal-Weight rating on Splunk (NASDAQ:SPLK) and maintained a price target of $110.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:34 pm

SGTX

Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Sigilon Therapeutics (NASDAQ:SGTX) and raises the price target from $7 to $21.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:33 pm

NKE

Morgan Stanley analyst Alex Kurtz has maintained an Overweight rating on Nike (NYSE:NKE) but lowered the price target from $130 to $127.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 12:31 pm